Transient receptor potential vanilloid 1 antagonism in neuroinflammation, neuroprotection and epigenetic regulation: potential therapeutic implications for severe psychiatric disorders treatment. (April 2020)

• Record Type: Journal Article
• Authors: Escelsior, Andrea; Sterlini, Bruno; Belvederi Murri, Martino; Valente, Pierluigi; Amerio, Andrea; di Brozolo, Manfredo Radicati; da Silva, Beatriz Pereira; Amore, Mario
• Is Part Of: Psychiatric genetics. Volume 30:Number 2(2020:Apr.)
• Publication Date: 2020-04
• Subjects: bipolar disorder -- epigenetic regulation -- neuroinflammation -- neuroprotection -- schizophrenia -- transient receptor potential vanilloid 1; Mental illness -- Genetic aspects -- Periodicals; Periodicals; 616.89042
• DOI: 10.1097/YPG.0000000000000249
• Languages: English
• ISSNs: 0955-8829

Abstract

Abstract : Transient receptor potential vanilloid 1 (TRPV1) is a polymodal cation channel gated by a large array of chemical and physical stimuli and distributed across different brain regions on neuronal and glial cells. Preclinical studies indicate that TRPV1 might be a target for the treatment of anxiety, depression and addictive disorders. The aim of this narrative review is to focus on studies examining the effects of TRPV1 antagonism on neuroinflammation, neuroprotection and epigenetic regulation. Results suggest that TRPV1 modulation leads to pro- or anti-inflammatory effects depending on the cytokine environment and that the TRPV1 antagonism can switch the microglia towards an anti-inflammatory phenotype. Moreover, TRPV1 inhibitors have neuroprotective properties through the regulation of calcium levels. Finally, TRPV1 antagonism exerts regulatory effects on genes involved in synaptic and cognitive functions through histone deacetylase 2 inhibition. These findings highlight different mechanisms that may underlie the efficacy of TRPV1 antagonists in animal models of severe psychiatric disorders.